Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.Check Now!

Home
report store
axial spondyloarthritis axspa epidemiology forecast insight

SALE

Axial Spondyloarthritis (axSpA) - Epidemiology Insight - 2034

Published Date : 2025

Pages : 100

Region : United States,

SALE

Summary
TOC Table of Content
LOT
- Sample Request

axial spondyloarthritis axspa epidemiology forecast insight

DelveInsight’s ‘Axial Spondyloarthritis (AxSpA)—Epidemiology Forecast–2034’ report delivers an in-depth understanding of the axSpA, historical and forecasted epidemiology as well as the axSpA trends in the United States.

Geographies Covered

The United States

Study Period: 2021-2034

Axial Spondyloarthritis (axSpA) Disease Understanding

Axial spondyloarthritis (axSpA) is a chronic, immune-mediated, inflammatory condition that consists of two subsets, which clinically have been defined as ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). Nr-axSpA is characterized by the absence of definitive x-ray evidence of structural damage to the sacroiliac (SI) joint by plain x-ray. Since the SI joint x-ray interpretation is subjective, the distinction between nr-axSpA and AS is not absolute. Sacroiliitis (inflammation of the SI joint) and inflammation of the spine are predominant features of axSpA; hence patients typically present with inflammatory back pain. Other manifestations, such as enthesitis, dactylitis, peripheral arthritis, anterior uveitis, psoriasis, and inflammatory bowel disease, are common. Over time many patients with nr-axSpA develop the structural damage of sacroiliac joints, ultimately progressing to AS; however, some nr-axSpA patients will never advance to this stage. The clinical manifestations for axSpA and nr-axSpA are similar to the patients’ disease burden experience.

Patients with axSpA commonly complain of back pain that starts before 45 years of age. Back pain’s characteristic features include chronicity (>3 months), insidious onset, improvement with exercise, an occurrence at night with improvement upon waking, and no rest. Inflammatory back pain (IBP) criteria are essential in screening for axSpA. Among at-risk patients, the sensitivity of IBP (approximately 70–95%) for axSpA is relatively high (back pain >3 months with onset age).

Continued in the report…..

Axial Spondyloarthritis (axSpA) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Prevalent Cases of Axial Spondyloarthritis, Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis scenario in the United States, from 2021 to 2034.

Axial Spondyloarthritis (axSpA) Detailed Epidemiology Segmentation

The total prevalent population of Axial Spondyloarthritis (axSpA) in the US was estimated to be 3,122,331 in 2020 which is anticipated to rise till 2034. Out of the total prevalent population, 1,336,050 cases were diagnosed in 2020.
In the epidemiology model, different age-groups are included, i.e., 18–29 years, 30–39 years, 40–49 years, 50–59 years, 60–69 years, and 70+ years. It is estimated that the most prevalent age-group for axSpA in the United States was 40–49 years in 2020.
The total prevalent population of nr-axSpA and AS in the US was estimated to be 1,821,360 and 1,300,971 in 2020, respectively.
In 2020, out of the total diagnosed cases of nr-axSpA, 670,252 cases had HLA-B27 gene mutation, and 109,111 cases involved other genes (ERAP 1, IL-12, IL-17, and IL-23). Additionally, in cases of AS, out of the total diagnosed cases in 2020, 501,019 cases involved HLA-B27 gene, and 55,669 cases had other genes involvement.
The prevalent population of AS showed a male predominance, whereas nr-axSpA showed a female predominance. Out of the total diagnosed population of nr-axSpA 779,363 cases in the US, 335,126 and 444,237 cases were contributed by males and females, respectively, in 2020.

Scope of the Report

The report covers the descriptive overview of AXSPA, explaining its causes, symptoms, pathophysiology, and genetic basis.
The report provides insight into the historical and forecasted patient pool covering the United States.
The report assesses the disease risk and burden and highlights the unmet needs of AXSPA.
The report helps to recognize the growth opportunities in the United States with respect to the patient population.
The report provides the segmentation of the disease epidemiology for the United States by Total Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis, Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis.

“The diagnosis of axial spondyloarthritis (axSpA) can be tough to spot as so many people have back pain—its main symptom. Additionally, there are no specific lab tests to identify the condition. All these factors play a major role in the low diagnosis of axSpA. Gender difference in both the types of axSpA has shown different trend. In case of nr-axSpA, female dominance is observed, whereas in AS, male dominance is there.”

Report Highlights

10-Year Forecast of axSpA
United States Coverage
Total Prevalent Cases of Axial Spondyloarthritis
Total Diagnosed Prevalent Cases of Axial Spondyloarthritis
Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis
Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis

Key Questions Answered

What are the disease risk, and burden of axSpA?
What is the historical axSpA patient pool in the United States?
What would be the forecasted patient pool of axSpA at the United States level?
What will be the growth opportunities across the United States with respect to the patient population pertaining to axSpA?
Out of the above-mentioned countries, which country would have the highest prevalent population of axSpA during the forecast period (2025-2034)?
At what CAGR the population is expected to grow across the United States during the forecast period (2025-2034)?

Reasons to buy

The AXSPA report will allow the user to -

Develop business strategies by understanding the trends shaping and driving the United States axSpA epidemiology forecast.
The axSpA epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
The axSpA epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

Patient Segmentation
Disease Risk and Burden
Risk of disease by the segmentation
Factors driving growth in a specific patient population

List of Tables:

List of Table

Table 1: Summary of Axial Spondyloarthritis (AxSpA) Epidemiology, and Key Events (2021-2034)

Table 2: Summary of Axial Spondyloarthritis (AxSpA) Market, and Key Events (2021-2034)

Table 3: Confirmed and putative biomarkers for diagnosis, disease progression, and response to treatment in AS and axSpa

Table 4: Summary of the Differential Diagnosis of AxSpA

Table 5: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2018−2030)

Table 6: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Table 7: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Table 8: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Table 9: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

List of Figures:

List of Figures

Figure 1: Pathology of entheses in AS

Figure 2: Risk Factors for AS

Figure 3: Functional roles of AS-associated genes

Figure 4: Antigen processing and presentation: a potential link to AS

Figure 5: Multiple roles for HLA-B27 in the pathogenesis of AS

Figure 6: Immune cells involved in the initiation, progression, and regulation of AS

Figure 7: The role of the gut in driving joint inflammation in AS

Figure 8: Potential mechanisms by which ERAP variants operate to influence disease risk in AS

Figure 9: Algorithm for the Diagnosis or Exclusion of AxSpA

Figure 10: ASAS classification criteria for axSpA

Figure 11: Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. ASDAS, Ankylosing Spondylitis Disease Activity Score

Figure 12: Recommendations for the treatment of axial spondyloarthritis

Figure 13: Total Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Figure 14: Total Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Figure 15: Gender-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Figure 16: Age-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Figure 17: Gene-specific Diagnosed Prevalent Cases of Axial Spondyloarthritis in the United States (2021-2034)

Tags:

License Type

Offer